Navigation Links
Bioponic Phytoceuticals Announces Curecumin(TM) May Lower Heart Failure Risk

KULA, Maui, April 16 /PRNewswire/ -- Bioponic Phytoceuticals, Inc. (OTC: BPYT) ("Bioponic" or "the Company") today announced that curcumin, the key ingredient in the Company's Curecumin(TM) product (a Bioresonant Phytotherapeutic(R) form of curcumin in a liquid delivery system) may be an important treatment for lowering heart failure risk. Bioponic currently sells Curecumin in a 1 oz. oral spray and a 1 oz. nasal pump spray bottle. Research findings and product information on Curecumin's many therapeutic qualities can be found at

In a recent study entitled, "Curcumin prevents and reverses murine cardiac hypertrophy," published in the February 2008 edition of the Journal of Clinical Investigation, researchers found that when the herb was given orally to a variety of mouse models with enlarged hearts (hypertrophy), it can prevent and reverse hypertrophy, restore heart function and reduce scar formation.

"Whether you are young or old; male or female; the larger your heart is, the higher your risk is for developing heart attacks or heart failure in the future," explains Dr. Liu, a cardiologist in the Peter Munk Cardiac Centre at the Canadian Institutes of Health Research - Institute of Circulatory and Respiratory Health. If clinical trials of curcumin support initial findings of heart enlargement prevention, it may offer hope for millions of patients with heart enlargement. Dr. Liu, who holds the Heart and Stroke Foundation's Polo Chair Professor in Medicine and Physiology at the University of Toronto, says that curcumin may be a safe and effective means of preventing heart failure in the future. This study was funded by the Heart and Stroke Foundation and the Canadian Institutes of Health Research.

"Curcumin has been the subject of extensive research over the past few years, and has been shown to protect the liver, inhibit tumors, reduce inflammation and prevent the formation of the amyloid beta plaques which cause Alzheimer's Disease. We are encouraged by yet another study that suggests the versatile curcumin may lower heart failure risk," said Steven M. Schorr, Chairman and CEO of Bioponic. "More than 5 million Americans are living with heart failure, and 550,000 new cases are diagnosed each year, according to the American Heart Association. The potential that our Curecumin(TM) product ( could provide a viable treatment strategy for those at risk for heart failure is very exciting. If proven effective, we may have an efficacious, cost effective, natural treatment for heart failure sufferers."

About Bioponic Phytoceuticals

Bioponic Phytoceuticals is engaged in the development, production and distribution of Bioresonant Phytotherapeutic(TM) products. The Company has developed several branded product lines (including the nasal spray: Flight Spray(R) ( and the skincare product Hawaiian Healing Mist(TM)). Bioponic is focused on the production of natural products that are used to promote health and well-being. Visit

All statements other than statements of historical fact included in this press release are "forward-looking statements" within the meaning of federal securities laws. Such forward-looking statements are subject to a number of risks and uncertainties, some of which are beyond the Company's control.

SOURCE Bioponic Phytoceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Bioponic Phytoceuticals Announces Master Distributorship With Natures Best Covering 1,000 West Coast Retailers
2. Bioponic Phytoceuticals Introduces All Natural Baby Product Suite Gentle Mother
3. Bioponic Phytoceuticals Retains OTC Financial Network for Investor Relations
4. Lotus Pharmaceuticals, Inc. Announces Conference Call to Discuss Fourth Quarter and Fiscal Year 2007 Results
5. Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
6. Dubai Cares Announces 12 Country Plan to Educate and Empower Children in Developing Nations
7. ECO2 Plastics, Inc. Reports 2007 Year End Financial Results, Announces FDA Filing and Provides Outlook for 2008
8. Law Offices of Howard G. Smith Announces Investigation on Behalf of Current and Former Employees of Inverness Medical Innovations, Inc. Who Invested in the Inverness Medical Innovations, Inc. Employee Savings Plan
9. The Pancreatic Cancer Action Network Announces Its 2008 Research Grant Awards Totaling Over $1 Million in New Research Funding
10. Parallel Software Announces Integrated Credit Card Processing for MacPractice MD, DDS, DC and 20/20
11. HealthSouth Announces Date of 2008 First Quarter Earnings Conference Call
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... Canada (PRWEB) , ... June 25, 2016 , ... Conventional ... pursuit of success. In terms of the latter, setting the bar too high can ... risk more than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... LEXINGTON, Mass. , June 24, 2016   ... specialty pharmaceutical company developing innovative inhaled drugs, announced today ... when Russell Investments reconstituted its comprehensive set ... 2016. "This is an important milestone for ... "It will increase shareholder awareness of our progress in ...
(Date:6/23/2016)... HOUSTON , June 23, 2016  MedSource ... platform as its e-clinical software solution of choice.  ... the best possible value to their clients by ... nowEDC.  The preferred relationship establishes nowEDC as the ... pricing for MedSource,s full-service clients.  "nowEDC has long ...
(Date:6/23/2016)... Research and Markets has announced the addition ... Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, Binder, ... Forecast to 2021" report to their offering. ... excipients market is projected to reach USD 8.1 Billion ... forecast period 2016 to 2021. The ...
Breaking Medicine Technology: